发明名称 |
Diagnosis of neurodegenerative diseases |
摘要 |
The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No. P51884); alpha-fibrinogen precursor (SwissProt Acc. No. P02671); IGHG4 protein (Swiss Prot Acc. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed. |
申请公布号 |
US9028801(B2) |
申请公布日期 |
2015.05.12 |
申请号 |
US200511792686 |
申请日期 |
2005.12.07 |
申请人 |
Electrophoretics Limited;Medical Research Council;University College London |
发明人 |
Ward Malcolm Andrew;Collinge John;Jackson Graham Stuart;McGregor Emma;Leeds Nicola Louise;Campbell James;Westbrook Jules Arthur;Byers Helen Louise |
分类号 |
A61B5/145;G01N33/48;C07K14/805;C07K14/75;C07K14/705;G01N33/68 |
主分类号 |
A61B5/145 |
代理机构 |
Arent Fox LLP |
代理人 |
Arent Fox LLP |
主权项 |
1. A method comprising:
providing a blood, serum, or plasma sample from a human subject; subjecting the sample to two dimensional gel electrophoresis to yield a stained gel; and quantifying an increased or decreased concentration of each of a plurality of proteins in the sample, compared with a sample of a control, normal human subject, the plurality of proteins having an increased concentration being selected from the group consisting of: beta-actin (SwissProt Acc. No. P60709); apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); hemoglobin beta chain (SwissProt Acc. No. P02023); and alpha-1-antitrypsin (SwissProt Acc. No. P01009); and the plurality proteins having a decreased concentration being selected from the group consisting of: plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No. P51884); alpha-fibrinogen precursor (SwissProt Acc. No. P02671); IGHG4 protein (Swiss Prot Acc. No. Q8TC63); and immunoglobulin lambda heavy chain, wherein the increased or decreased concentration of each of the plurality of proteins is detected by an increased or decreased intensity of a protein-containing spot on the stained gel, compared with a corresponding control gel. |
地址 |
Cobham Surrey GB |